<DOC>
	<DOCNO>NCT02924584</DOCNO>
	<brief_summary>Breast cancer common cancer Taiwanese woman . Most diagnosed relatively early stage . Only 700 metastatic breast cancer register Official Cancer Registration 2012 , than11,305 register early breast cancer . With broadly application aromatase inhibitor , hormonal-receptor-positive breast cancer patient survive longer longer . However , prevalence metastatic breast cancer available yet . NHIA database coverage 90 % population Taiwan , thus appropriate surrogate prevalence . In retrospective database analysis , explore real world experience aromatase inhibitor use breast cancer Taiwan .</brief_summary>
	<brief_title>Clinical Outcome Of Hormonal Receptor Positive , Her-2 Negative Breast Cancer In Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>hormonal receptor positive , human epidermal growth factor receptor 2 negative breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hormonal receptor positive , human epidermal growth factor receptor 2 negative , breast cancer , aromatse inhibitor , overall survival , prevalence</keyword>
</DOC>